Jan‐Philipp Bach

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

Richard Dodel, Axel Rominger, Peter Bartenstein et al. · The Lancet Neurology · 2013 · 183 citations · Full text

Geriatric Neurology, Alzheimer's Disease, Medicine +12

Projected numbers of people with movement disorders in the years 2030 and 2050

Jan‐Philipp Bach, Uta Ziegler, Günther Deuschl et al. · Movement Disorders · 2011 · 159 citations

Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson’s Disease

Jan‐Philipp Bach, Maike Gold, David Mengel et al. · PLoS ONE · 2015 · 76 citations · Full text

α1-antitrypsin mitigates NLRP3-inflammasome activation in amyloid β1–42-stimulated murine astrocytes

Taraneh Ebrahimi, Marcus Immanuel Rust, Sarah Kaiser et al. · Journal of Neuroinflammation · 2018 · 69 citations · Full text

Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease

Jan‐Philipp Bach, Oliver Riedel, Jens Klotsche et al. · Journal of the Neurological Sciences · 2011 · 53 citations

Quality Of Life, Life Assessment, Treatment Costs +10